Peptide Schedule
DanuglipronSmall moleculeNo amino acid sequence. Icon reflects category theme only.Danuglipron Dosage Calculator
Danuglipron (PF-06882961) was Pfizer's attempt to enter the GLP-1 weight loss market with an oral small-molecule drug that could compete with injectable semaglutide and tirzepatide.
10mcg · 2x Daily
Summary: Add 0mL BAC water to your 120mg vial. Draw to < 0.1 units on a U-100 syringe for a 10mcg dose. This vial will last 0 doses.
Cycle Planner
Danuglipron Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~6-8 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Danuglipron Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mg | 2x Daily |
| Moderate | 80mg | 2x Daily |
| Aggressive | 120mg | 2x Daily |
Note: Danuglipron (PF-06882961) is an oral small-molecule GLP-1 receptor agonist — not a peptide — developed by Pfizer. Development was discontinued in April 2025 after a single participant in a dose-optimization study experienced potential drug-induced liver injury (resolved after stopping the drug). Twice-daily dosing was required due to the short ~6-8 hour half-life, though Pfizer was developing an extended-release once-daily formulation before discontinuation. No reconstitution needed — oral tablet. Phase 2b data showed significant weight loss but very high discontinuation rates (>50% across all doses).
About Danuglipron
Danuglipron (PF-06882961) was Pfizer's attempt to enter the GLP-1 weight loss market with an oral small-molecule drug that could compete with injectable semaglutide and tirzepatide. Unlike oral semaglutide (Rybelsus), which is still a peptide packaged with an absorption enhancer, danuglipron is a true small molecule — a non-peptide allosteric agonist of the GLP-1 receptor that survives the GI tract on its own. The Phase 2b trial in adults with obesity (626 participants) demonstrated meaningful weight loss, with placebo-adjusted reductions ranging from -5.0% to -12.9% at 26-32 weeks depending on dose. In type 2 diabetes trials, HbA1c reductions reached -1.16% versus placebo at the highest dose, with significant fasting glucose improvements. These are competitive numbers on paper. The problem was tolerability. Across all doses, more than 50% of participants discontinued treatment — compared to roughly 40% on placebo. About 38% dropped out specifically due to adverse events, mostly GI-related (nausea in 20-48% of participants, vomiting in 18-41%). The short half-life of approximately 6-8 hours meant twice-daily dosing, which compounded the tolerability issue. Pfizer pivoted to developing a once-daily extended-release formulation that met pharmacokinetic targets, but before it could reach Phase 3, a single participant in a dose-optimization study showed elevated liver enzymes consistent with potential drug-induced liver injury. Although the participant was asymptomatic and recovered after stopping the drug, and although liver enzyme elevations across the broader 1,400-person safety database were in line with approved GLP-1 agents, Pfizer chose to discontinue all danuglipron development in April 2025 after consulting with regulators. Danuglipron remains an instructive case in the oral GLP-1 space. Its clinical data showed that small-molecule GLP-1 agonism can produce weight loss comparable to injectable therapies, but the tolerability bar and safety requirements are high. Researchers may encounter it in literature comparisons with orforglipron, which ultimately succeeded where danuglipron did not.